Calming the storm: treating hypercoagulability and hyperinflammation in patients with COVID-19 KU Leuven
Laboratory for Clinical Infectious and Inflammatory Disorders, Anesthesiology and Algology, Laboratory of Intensive Care Medicine, Centre for Molecular and Vascular Biology, Ziekenhuis Oost-Limburg, GZA GasthuisZusters Antwerpen, Universiteit Hasselt
COVID-19 patients with hyperinflammation, hypercoagulability and hyperfibrinolysis are at increased risk for severe disease and mortality. Local dysfucntion of the viral receptor protein ACE2, which degrades the vasoactive peptides bradykinines, results in accumulation of vasoactive and inflammatory mediators that cause vasodilation and alveolar edema, leading to hypoxic respiratory failure and to activation of local and systemic ...